Submission of Intimation of In-Principle Approval for proposed preferential issue of equity shares pursuant to swap shares.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories has received BSE's in-principle approval for issuing 3,04,25,632 equity shares (about 3.04 crore shares) at a price not less than Rs. 91 per share to non-promoters on a preferential basis through a share swap arrangement. Each share has a face value of Rs. 10, meaning the issue price is at a significant premium over face value. The total indicative value of the swap is around Rs. 276-277 crore. This is a stock-based transaction where shares are being issued in exchange for assets or equity of another entity, not a cash fundraising. The approval is dated December 31, 2025, and the company must still complete the allotment and file a separate listing application within 20 days of allotment.
Shareholders should note this will dilute their holding by roughly 3.04 crore new shares issued to non-promoters, but no cash is being raised. The swap likely funds an acquisition or business combination, which could be positive if the acquired asset adds value, but details of what is being acquired are not provided in this filing.